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Abstract
Cigarette smoke is a major risk factor for a number of diseases including lung cancer and respiratory infections.
Paradoxically, it also contains nicotine, an anti-inflammatory alkaloid. There is increasing evidence that smokers
have a lower incidence of some inflammatory diseases, including ulcerative colitis, and the protective effect
involves the activation of a cholinergic anti-inflammatory pathway that requires the a7 nicotinic acetylcholine
receptor (a7nAChR) on immune cells. Obesity is characterized by chronic low-grade inflammation, which
contributes to insulin resistance. Nicotine significantly improves glucose homeostasis and insulin sensitivity in
genetically obese and diet-induced obese mice, which is associated with suppressed adipose tissue inflammation.
Inflammation that results in disruption of the epithelial barrier is a hallmark of inflammatory bowel disease, and
nicotine is protective in ulcerative colitis. This article summarizes current evidence for the anti-inflammatory effects
of nicotine in obesity and ulcerative colitis. Selective agonists for the a7nAChR could represent a promising
pharmacological strategy for the treatment of inflammation in obesity and ulcerative colitis. Nevertheless, we
should keep in mind that the anti-inflammatory effects of nicotine could be mediated via the expression of several
nAChRs on a particular target cell.
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Introduction
The major addictive component of tobacco, nicotine,
exerts anti-inflammatory effects in multiple cell types
and has been shown to benefit various disorders in
which an inflammation-related mechanism is implicated.
Chronic low-grade inflammation is a key feature of obe-
sity, which is characterized by the elevated production
of pro-inflammatory cytokines by the adipose tissue
itself [1-3]. Chronic and relapsing inflammation is at the
core of inflammatory bowel disease (IBD), which is
characterized by activation of the pro-inflammatory
transcription factor nuclear factor-B( N F - B) [4] and
increased expression of pro-inflammatory cytokines
such as tumor necrosis (TNF)-a in immune cells in the
mucosa of IBD patients [5,6]. Nicotine has been proven
effective in reducing obesity-related inflammation and
insulin resistance [7] and attenuating inflammation and
improving gut function in patients with active colitis [8].
In fact, ulcerative colitis patients with a history of
smoking usually acquire their disease after they have
stopped smoking [9-11]. Patients who smoke intermit-
tently often experience an improvement in their colitis
symptoms during the periods when they smoke [9,12].
Therefore the development of drugs designed to sup-
press the aberrant inflammatory response in obesity and
ulcerative colitis may be of significant help in giving
relief to patients.
Recent studies suggest that the parasympathetic ner-
vous system, in particular the efferent vagus nerve, regu-
lates immune responses via the peripheral release of
acetylcholine (ACh) [13,14]. Activation of the “choliner-
gic anti-inflammatory pathway” inhibits NF-B signaling
through the a7 nicotinic acetylcholine receptor
(nAChR) on immune cells such as macrophages
[13,15,16] or bone marrow-derived dendritic cells [17].
Thus, the cholinergic anti-inflammatory pathway could
be exploited to suppress inflammation in obesity and
gastrointestinal (GI) dysfunction. This article will discuss
recent advances in understanding the anti-inflammatory
effects of nicotine in obesity and gut dysfunction,
including ulcerative colitis.
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cytokines
There is no doubt that the net effect of cigarette smoking
is pro-inflammatory primarily as a result of increased oxi-
dative stress, which occurs when the amount of reactive
oxygen species (ROS) generated in cells exceeds the capa-
city of normal detoxification systems [18,19]. Oxidative
stress is one potential explanation for the enhanced DNA
breaks in smokers [20]. Thus, it has implications for
understanding the mechanisms by which smoking induces
organ damage. There is overwhelming medical and scien-
tific consensus that cigarette smoking causes lung cancer,
heart disease, emphysema, and other serious diseases in
smokers. Cigarette smoke contains molecules that act as
potent carcinogens (e.g., benzo[a]pyrene), as well as a large
amount of ROS forming substances such as catechol or
hydroquinone. However, nicotine, while being the addic-
tive agent, is often viewed as the least harmful of these
compounds. In fact, nicotine exhibits anti-inflammatory
properties in many systems [15,16,21,22].
Among the earliest findings in support of the anti-
inflammatory potential of nicotine was the observation
that nicotine altered the capacity of cells to respond to
the pro-inflammatory cytokine TNF-a [23] or inhibited
the release of this cytokine from the immune cell [21].
The vagus nerve can restrain serum TNF levels, and
prevents septic shock and organ damage [24]. Since
ACh is the principal neurotransmitter of the vagus
nerve, preliminary studies analyzed the potential of cho-
linergic agonists to prevent TNF production in immune
cells [25]. These studies collectively defined an interac-
tion described as the “cholinergic anti-inflammatory
pathway” [21,22]. As defined in these studies, the anti-
inflammatory properties of nicotine are generally
restricted to a7nAChR function and require ACh
release from vagal efferents [21].
Cytokines are low-molecular-weight proteins released
during activation of the inflammatory cascade, which
after binding to specific receptors affect immune cell
differentiation, proliferation, and activity. In general,
cytokines can be divided into those with predominantly
pro-inflammatory actions and those with anti-inflamma-
tory actions. Pro-inflammatory cytokines include TNF-
a, interleukin (IL)-1b, IL-6, and IL-8. TNF-a is a pleio-
tropic cytokine involved in many of the physiological
responses to infection, trauma, and cancer. In addition,
it has been strongly implicated as a mediator of sepsis
and studies of sepsis have shown elevated circulating
levels of this cytokine [26]. Anti-inflammatory cytokines
include IL1 receptor antagonist, IL-10, IL-13, and TNF-
binding proteins 1 and 2 (for review see [27]).
ACh and nicotine inhibit TNF-a and NF-Bp r o d u c -
tion from lipopolysaccharide (LPS)-stimulated human
macrophages and splenocytes [24,28]. Both the vagus
nerve and nicotine exert their inhibitory effects through
the activation of Jak2 and STAT3 [15] and the anti-
inflammatory action of nicotine is mediated by tristetra-
polin (TTP) [29], an adenylate uridylate- rich element
binding protein that promotes the degradation of a
number of inflammatory mediators including TNF-a
Nicotine-activated STAT3 signaling induces the expres-
sion of TTP in macrophages and, in turn, TTP plays a
k e yr o l ei nn i c o t i n e - i n d u c e d anti-inflammatory effect
through destabilization of TNF-a transcripts. Since an
excess of TNF-a is involved in many inflammatory dis-
eases, the inhibition of TNF-a production through the
modulation of nicotine-STAT3-TTP signaling pathway
may have wide-ranging clinical implications. Interest-
ingly, TTP-knockout mice develop severe inflammatory
arthritis, autoimmune dysfunction, and myeloid hyper-
plasia, demonstrating the importance of TTP in limiting
the inflammatory response [30].
ACh and nicotine also reduce the concentration of
high mobility group box 1 (HMGB1) protein production
by macrophages in sepsis patients [31]. HMGB1, a
nucleosome protein that acts as a pro-inflammatory
cytokine, stimulates other pro-inflammatory cytokines
(TNF-a,I L - 1 b, and IL-8) and promotes epithelial cell
permeability [31]. Treatment with nicotine attenuated
serum HMGB1 levels, decreased the clinical signs of
sepsis, provided significant protection against death and
improved survival in “established” sepsis [31]. Addition-
ally, nicotine treatment was not started until 24 h after
the induction of lethal peritonitis in mice indicating that
the cholinergic anti-inflammatory pathway can modulate
t h ei n f l a m m a t o r yr e s p o n s ee v e ni ne s t a b l i s h e ds e p s i s
[26].
The cholinergic anti-inflammatory pathway
In the GI tract, the vagus nerve regulates motility and
digestive function via the activation of nAChRs classi-
cally found on enteric neurons (See Figure 1; [32]).
However, non-neuronal cells, including immune cells
t h r o u g h o u tt h eb o d ya l s oe x p r e s sn A C h R sw h e r et h e y
contribute to diverse physiological processes including
immunomodulation [17].
In general, there are two major nAChR subtypes that
are composed of either homomeric subunits (e.g.,
a7nAChR) or combinations of alpha (a)a n db e t a( b)
subunits, and it is the final subunit configuration that
imparts significant functional and pharmacological dif-
ferences among these receptors (for review see [33]).
Neuronal nAChRs are composed of a2-a9a n db2-b4
subunits and are divided into two types. The first type is
composed of a heteromeric pentamer of a2-a6a n db2-
b4 and does not bind a-bungarotoxin (BTX). The sec-
ond type is composed of a homomeric pentamer of a7-
a9 and can bind aBTX. The a7nAChR subunit exhibits
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2+ permeability and thus plays an
important role in Ca
2+-dependent events, such as neuro-
transmitter release, cell survival and apoptosis. The
expression of a7nAChR by macrophages and other
immune cells suggests that it also plays a role in regulat-
ing tissue inflammation. In fact, a7nAChR is essential in
mediating the anti-inflammatory effect of ACh [16].
The cholinergic anti-inflammatory pathway is a brain-
to-immune mechanism that regulates inflammatory
responses via a7-nAChR-dependent, vagus nerve signal-
ing. Studies by Borovikova et al. demonstrated the
potency of the vagus nerve to inhibit TNF-a production
by macrophages after systemic endotoxin [13]. Perito-
neal and peripheral blood mononuclear cell-derived
macrophages express a7-nAChRs and vagal nerve sti-
mulation or exogenous ACh has been shown to inhibit
NF-B transcriptional activity and pro-inflammatory
cytokine production [16,31]. Studies indicate that ACh
post-transcriptionally suppresses TNF synthesis and
inhibits the release of IL-1b, IL-6, and IL-8 without pre-
venting the release of the anti-inflammatory cytokine
IL-10 [13]. In addition, electrical vagal nerve stimulation
has been shown to ameliorate disease in animal models
of inflammatory conditions including sepsis [13], ische-
mia reperfusion [34], hemorrhage [35] and postoperative
ileus [15]. Thus, the production of pro-inflammatory
cytokines from peripheral macrophages can be attenu-
ated by vagal activity such that activation of this sys-
temic “cholinergic anti-inflammatory pathway” improves
survival during experimental sepsis [31,36]. In contrast,
chemical as well as surgical blockade of vagus nerve sig-
naling significantly worsened colitis and enhanced colo-
nic inflammatory mediators in two experimental models
of colitis [37,38], an effect that was counteracted by
nicotine administration.
Additional evidence supporting the role of the vagus
nerve in modulating the inflammatory response comes
from studies of rats subjected to cecal ligation and
puncture (CLP, a model of polymicrobial sepsis) where
electrical stimulation of the efferent vagus nerve signifi-
cantly decreased serum TNF-a production, hepatic
TNF-a synthesis, and prevented the development of
CLP-induced hypotension. In contrast, bilateral cervical
vagotomy led to substantially increased serum and hepa-
tic TNF-a levels and accelerated the development of
shock [39].
Naturally occurring CD4(+)CD25(+) regulatory T cells
(Tregs) are essential for the active suppression of auto-
immunity, and Tregs from naïve C57BL/6J mice express
a7-nAChR [40]. Moreover, nicotine via its action on
a7nAChR seems to be a critical regulator for the immu-
nosuppressive function of CD4(+)CD25(+) Tregs in
mice [40]. Furthermore, nicotine reduced NF-B-
mediated transcription as measured by IL-2 and IB
transcription [41]. Together, these results suggest a
“direct” link between the vagus nerve and immune cells,
where ACh released by the vagus nerves activates
a7nAChR on immune cells to inhibit cytokine
production.
However, recent studies have shown that the spleen is
a major source of inflammatory cytokines involved in
the initiation of systemic inflammation [24] and that the
vagus nerve can control systemic inflammation by inhi-
biting cytokine production in the spleen [24]. In fact,
splenectomy prevents the anti-inflammatory potential of
the vagus nerve. Since the vagus nerve does not inner-
vate the spleen but terminates in the celiac-mesenteric
ganglia [42], these results were surprising. Recent find-
ings indicate that ACh released by the vagus nerve in
the celiac-mesenteric ganglia activates postsynaptic
a7nAChR of the splenic nerve, leading to the release of
norepinephrine in the spleen [43]. Splenic norepinephr-
ine can inhibit cytokine production from macrophages
via b-adrenergic receptors [33]. Thus, both the vagus
nerve and a7nAChR agonists require the splenic nerve
to control systemic inflammation in sepsis. Moreover,
both the parasympathetic vagus nerve and the sympa-
thetic splenic nerve can team together and coordinate to
control systemic inflammation in life threatening condi-
tions such as sepsis.
Cholinergic signaling to the spleen also plays an
important role in modulating leukocyte migration dur-
ing inflammation. Endothelial cells express the
Figure 1 Immunohistochemical localization of nicotinic
acetylcholine receptors (nAChRs) in the guinea pig enteric
nervous system. Confocal image of a whole mount preparation of
the myenteric plexus of the stomach stained using monoclonal
antibody mAb35, which recognizes alpha bungarotoxin-insensitive
nAChRs. Note the punctate staining around neuronal cell bodies.
Reprinted from Wiley-Liss, Inc: The Journal of Comparative Neurology
390(4): 497-514 Copyright 1998 [32].
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tor reduces both chemokine production and adhesion
molecule expression by endothelium [44]. However, the
endothelium is not directly innervated by the vagus
nerve. Recent studies demonstrate that cholinergic sig-
naling to the spleen regulates leukocyte migration to
sites of tissue inflammation by reducing adhesion mole-
cule expression [45]. Thus, the spleen is a critical inter-
face between the cholinergic anti-inflammatory pathway
and the system regulation of immune cell trafficking
and the cholinergic regulation of neutrophil migration is
mediated, in part, through modulation of CD11b expres-
sion on the surface of neutrophils [45]. Vagus nerve sti-
mulation significantly attenuates neutrophil surface
CD11b surface expression levels only in the presence of
an intact and innervated spleen. Activating this mechan-
ism through direct stimulation of the endogenous vagus
nerve pathway to the spleen (via splenic innervation) or
through administration of pharmacological cholinergic
agonists (which act through the spleen) may have
important therapeutic potential to inhibit excessive and
deleterious neutrophil migration into inflamed or
infected tissues [45].
Nicotine ameliorates obesity-induced inflammation and
insulin resistance
The World Health Organization has estimated that by
2015 approximately 2.3 billion adults will be over-
weight and more than 700 million obese [46]. The
increase in obesity is associated with corresponding
increases in type 2 diabetes, hypertension, cardiovascu-
lar disease and cancer [47]. Obesity is also associated
with an increased incidence of gastrointestinal (GI)
disorders [48] suggesting effects on the enteric nervous
system (ENS), which controls virtually all gut functions
(for review see [49]).
The appetite-suppressing effect of tobacco is well
established and a major driver of smoking behavior [50].
A negative correlation among smoking, body weight,
and caloric intake has been well demonstrated across
species [51-53]. Mice exposed to three cigarettes, three
times a day for 4 days displayed a marked decrease in
food intake and body weight [52]. Animals exposed to 4
weeks of cigarette smoke had reduced food intake, body
weight gain, fat mass, as well as plasma leptin concen-
tration relative to control mice whereas equivalent food
restriction only decreased body weight [54]. Moreover,
potential weight gain on smoking cessation may deter
people from quitting [51,52,55-57]. Such individuals
should be made aware that smoking is not an efficient
way to control body weight. Although the mechanisms
of appetite regulation by smoking are unknown,
hypothalamic energy balance circuits were disturbed by
cigarette smoke exposure as evidenced by the altered
neuropeptide Y (NPY) concentration in the hypothala-
mic paraventricular nucleus, suggesting NPY signaling is
involved in the appetite-suppressive effects of cigarette
smoking [54].
Nicotine, the principal addictive constituent of
tobacco, has been shown to suppress appetite and
attenuates obesity in many studies, but the underlying
mechanism is not clear. Nicotine receptors are highly
expressed in the hypothalamus and medulla, in nuclei
that play a significant role in appetite regulation. Activa-
tion of hypothalamic a3b4 nAChRs led to the activation
of anorexigenic pro-opiomelanocortin (POMC) neurons
in the arcuate nucleus and subsequent stimulation of
melanocortin 4 receptors, which were critical for the
nicotine-induced decrease in food intake in mice [58].
Nicotine inhibited excitatory synaptic activity recorded
in NPY, but not POMC neurons and also excited the
arcuate nucleus hypocretin/orexin neurons that enhance
cognitive arousal, but the responses were smaller than
in POMC neurons [59]. Increased NPY expression in
food-restricted rats was inhibited by nicotine adminis-
tration [60] and hypothalamic NPY Y1 receptor density
was reduced by chronic nicotine treatment [61].
Together, these findings indicate that nicotine has a
number of actions on hypothalamic neurons that could
contribute to the reduced food intake and weight loss
associated with smoking.
Low-grade inflammation is a key feature of obesity
and links obesity to insulin resistance, impaired glucose
tolerance and even diabetes. Features of obesity-induced
inflammation include increased production of pro-
inflammatory cytokines, including TNF-a and IL-6 by
white adipose tissue (WAT), and the activation of a net-
work of pro-inflammatory signaling pathways, including
the c-Jun NH2-terminal kinase (JNK) and inhibitor of
NF-B kinase b (IKKb), which may have local effects on
WAT physiology but also systemic effects on other
organs [62].
Recent data indicate that obese WAT is infiltrated by
macrophages, which may be a major source of locally-
produced pro-inflammatory cytokines [63,64]. TNF-a
and other pro-inflammatory molecules in WAT have
been implicated in the development and maintenance of
obesity-induced adipose tissue inflammation [62]. TNF-
a is overproduced in the WAT of several animal models
of obesity. Furthermore, macrophage-specific disruption
of the NF-B pathway resulted in improved insulin sen-
sitivity [65]. Ablation of JNK1 in hematopoietically-
derived cells including macrophages also protected mice
from diet-induced inflammation and insulin resistance
without affecting adiposity [66]. These data collectively
demonstrate that macrophage inflammation is an impor-
tant mediator of obesity-induced insulin resistance.
Interestingly, weight loss is associated with a reduction
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ment of the inflammatory profile of gene expression.
The cholinergic anti-inflammatory pathway has been
extensively studied in terms of its immunomodulatory
function against chronic inflammatory disorders [67,68].
Recent studies showed that activation of the cholinergic
anti-inflammatory pathway ameliorates obesity-induced
inflammation and insulin resistance [7]. Activation of
the cholinergic anti-inflammatory pathway by low-dose
nicotine significantly suppressed inflammation in adi-
pose tissue, an important site in mediating obesity-
induced inflammation in genetically obese (db/db)a n d
diet-induced obese (DIO) mice. This was associated
with a significant improvement in glucose homeostasis
and insulin sensitivity without changes in body weight.
In addition, macrophages isolated from mice deficient in
a7nAChR had elevated pro-inflammatory cytokine pro-
duction in response to free fatty acids and TNF-a,
known agents causing inflammation and insulin resis-
tance. Furthermore, nicotine significantly suppressed
TNF-a-induced cytokine production in wild type, but
not a7nAChR -/- macrophages [7]. Overall, these find-
ings suggest that nicotine and specific a7nAChR ago-
nists may be beneficial in the prevention and treatment
of obesity-induced inflammation and insulin resistance.
However, there is also evidence that heavy smoking
affects body fat distribution that is associated with cen-
tral obesity and insulin resistance [69]. Moreover, smok-
ing appears to aggravate insulin resistance in persons
with type 2 diabetes and to impair glycemic control
[70]. Other factors such as low physical activity and
poor diet could counterbalance and even overtake the
slimming effect of smoking. Clearly, the pathophysiolo-
gical factors involved in the association among smoking
and obesity are little explored, and remain to be
elucidated.
Nicotine alleviates ulcerative colitis
One of the earliest noted effects of nicotine on a periph-
eral tissue was in inflammation of the intestine. Early
reports mentioned patients with ulcerative colitis who
upon cessation of smoking experienced more severe dis-
ease progression, which was ameliorated by returning to
smoking [71-73]. In contrast, patients with Crohn’sd i s -
ease experienced severe disease when smoking, requiring
the immediate cessation of any tobacco product use
[74]. Crohn’s disease is a chronic inflammatory disease,
which might affect any part of the GI tract, causing a
wide range of complications including ulceration, fibros-
tenosis, and fistula development resulting in symptoms
like abdominal pain, fever, diarrhea, and weight loss
during episodes with flare-ups. Smoking also worsens
the course of Crohn’s disease by increasing the risk of
developing fistulas and strictures as well as accelerating
the need for surgery, probably due to an increased influx
of neutrophils into the intestinal mucosa [75,76]. These
detrimental effects of smoking in Crohn’s disease could
also be related to the nicotine-induced suppression of
antimicrobial activity and immune responses by macro-
phages [77], which might further compound any defi-
ciency in the host response to luminal bacteria.
Ulcerative colitis is a chronic IBD characterized by
pathological mucosal damage and ulceration, which
usually is limited to the rectum (40%) or distal colon
(40%) [78]. Patients with ulcerative colitis have increased
intestinal permeability, which is most likely caused by
the ulcerations observed in ulcerative colitis, causing
diarrhea, a primary exudate of the disease [79]. The
annual incidence of ulcerative colitis in the United
States during the period 1996-2002 was 12 cases per
100,000 and has risen in recent decades [80]. Ulcerative
colitis typically presents as a relapsing disorder marked
by attacks of diarrhea containing blood and mucus that
sometimes persists for months only to recur after an
asymptomatic interval of months to years. During
relapses, acute attacks of ulcerative colitis cause a mas-
sive infiltration of neutrophils and mononuclear cells
into the lamina propria and submucosa. During remis-
sions of active disease, granulation tissues fill the ulcer
craters accompanied by regeneration of the mucosal
epithelium [78].
The recommended first-line therapy of colitis is the
anti-inflammatory agent 5-aminosalicytic acid (5-ASA;
mesalamine), which targets peroxisome proliferator-acti-
vator receptor-g (PPAR-g). PPAR-g is known to be
involved in ulcerative inflammation; however, indepen-
dent actions of 5-ASA include the inhibition of prosta-
glandin synthesis and NF-B). 5-ASA may also act as an
antioxidant by scavenging oxygen free radicals. In addi-
tion to 5-ASA, nicotine has been found to alleviate
ulcerative colitis [81]. In fact, ulcerative colitis is largely
a disease of non-smokers and ex-smokers, and is
uncommon amongst smokers. Although the effects of
“smoking” should not be considered synonymous with
“nicotine”, there is clinical evidence to suggest that nico-
tine is responsible for this effect, as transdermal nicotine
has been used with beneficial effects in patients with
active disease [8]. A nicotine enema has also been devel-
oped and found to be of benefit when given as addi-
tional therapy in active distal ulcerative colitis [82].
Although the specific mechanisms underlying this effect
remain unclear, nicotine has a number of actions that
could be potentially beneficial, including effects on the
immune system [83,84] and gut motility [85].
Increased severity of colitis in mice deficient in a7nAChR
A major role of a7nAChR in colitis was demonstrated
by the increased severity of colitis induced by dextran
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a7nAChR-deficient mice lost significantly more body
weight and had increased levels of proinflammatory
cytokines in comparison to wild type mice as early as 3
days post-colitis [86]. In addition, neither nicotine nor a
selective a7nAChR agonist (choline chloride) attenuated
the degree of inflammation in a7nAChR-deficient mice.
Nicotine has been found to reduce the LPS-stimulated
production of TNF-a and IL-1b from peripheral blood
mononuclear cells from IBD patients [87]. Thus, it is
not surprising that excessive TNF-a production as
occurs in colitis can also be attenuated by activation of
a7nAChR [86].
Macrophages are an important component of the
inflammatory response in murine models of colitis and
in human IBD and are responsible for the production of
pro-inflammatory cytokines. Several groups have identi-
fied the a7nAChR on macrophages suggesting that
nicotine modulates the activity of these cells. However,
several immune cells (e.g., dendritic cells, mast cells)
express a7nAChR and other nAChR subtypes suggest-
ing that different types of immune cells are sensitive to
acetylcholine. An interesting issue to be addressed is
which nAChRs, or their respective levels of expression,
might participate in colitis and the differential response
to nicotine. In fact, very little is known about the signal-
ing pathways activated by nicotine or the mechanism
mediating nicotine-associated anti-inflammation in the
bowel. An immune regulating role for the cholinergic
nervous system may be particularly evident in intestinal
tissue, given the dense cholinergic innervation and the
abundant number of resident macrophages that popu-
late the intestinal mucosa and muscularis externa, of
which some are closely associated with cholinergic
fibers.
In isolated intestinal and peritoneal macrophages,
nAChR activation enhanced endocytosis and phagocyto-
sis and this effect induced a transiently enhanced muco-
sal passage of luminal bacteria, in agreement with the
role of ACh in stress-induced epithelial permeability
[88]. The effect was mediated via stimulated recruitment
of GTPase Dynamin-2 to the forming phagocytic cup
a n di n v o l v e dn A C h Ra4/b2, rather than a7nAChR.
However, despite enhanced luminal bacterial uptake,
ACh reduced NF-B activation and pro-inflammatory
cytokine production, while stimulating anti-inflamma-
tory interleukin-10 production [89].
a7nAChR agonists worsen colitis
Given the proposed role of the a7nAChR in mediating
the effects of stimulation of cholinergic anti-inflamma-
tory pathways, selective a7nAChR agonists may have
more therapeutic potential in ameliorating colitis than
nicotine. Snoek et al. [90] explored the effects of
nicotine and two selective a7nAChR agonists (AR-
R17779, GSK1345038A) on disease severity in two
mouse models of acute experimental colitis. Colitis was
induced by administration of DSS (1.5%) in the drinking
water or 2,4,6-trinitrobenzene sulphonic acid (TNBS; 2
mg) intrarectally. Nicotine, AR-R17779, or
GSK1345038A was administered daily by i.p. injection.
After 7 days clinical parameters and colonic inflamma-
tion were scored.
Nicotine and both a7nAChR agonists reduced the
activation of NF-B and pro-inflammatory mediator
release in whole blood and macrophage cultures. In
addition, treatment of DSS colitis with nicotine led to a
significant reduction in colonic edema and colonic IL-6
and IL-17 production. However, this reduction was not
marked enough to be reflected in clinical parameters
and histopathological scores. Treatment with the
a7nAChR agonists both displayed a bell-shaped dose-
response curve; the highest doses of AR-R17779 and
GSK1345038A significantly ameliorated clinical para-
meters, whereas lower doses of both compounds actu-
ally worsened or did not affect clinical parameters. It
should be borne in mind that several nAChRs are
expressed in the gut and on various cell types. Intestinal
mucosal macrophages express a4b2 nAChR and assist
in the surveillance of luminal antigen uptake by aug-
menting the uptake of luminal bacteria by mucosal
macrophages. Previous studies also point towards a role
in modulation of intestinal inflammation by the
a5nAChR [91](see Below). Thus, a combination of
selective a7nAChR, a4b2 nAChR and/or a5nAChR ago-
nists might be more appropriate in modulating intestinal
inflammation as a large array of AChRs are expressed in
the gut. Irrespectively, nicotine administration amelio-
rated disease in previous studies of experimental colitis
[37].
Dysfunction of Enteric Neural Circuits in Colitis
In addition to immune cells, neurons in the ENS express
a7nAChRs (see Figure 2; [32]). The ENS consists of the
intrinsic innervation of the bowel, a component of the
autonomic nervous system with the unique ability to
function independently from the CNS (for review, see
[49]). Enteric ganglia are organized into two major gang-
lionated plexuses, namely the myenteric (Auerbach’s)
and submucosal (Meissner’s) plexus, and contain a vari-
ety of functionally distinct neurons, including primary
afferent neurons, interneurons, and motor neurons,
synaptically linked to each other in microcircuits. While
the myenteric plexus mainly regulates intestinal motility,
the submucosal plexus together with nerve fibers in the
lamina propria are involved in regulating epithelial
transport. These nerves form networks within the
lamina propria of both crypts and villi with the terminal
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position not only to affect epithelial cell functions but
also to detect absorbed nutrients and antigens. Sub-
stances released from epithelial cells may act on nerve
terminals to change the properties of enteric neurons
and cause peripheral sensitization. Consequently, perma-
nent or even transient structural alterations in the ENS
disrupt normal GI function. Since the ENS controls the
motility and secretion of the bowel these abnormalities
indicate the impact of inflammation on neural signaling
in the ENS.
Several studies have demonstrated structural changes
within the ENS in gut inflammation (see [92] for
review). For example, damage to axons has been
observed in the inflamed human intestine in episodes of
IBD [93]. Other changes that occur in the ENS during
inflammation include altered neurotransmitter synthesis,
content, and release, changes in glial cell numbers and a
myenteric ganglionitis associated with infiltrates of lym-
phocytes, plasma cells and mast cells [94,95]. In fact,
consequences of intestinal inflammation, even if mild,
persist for weeks beyond the point at which detectable
inflammation has subsided [92].
To identify cells through which nicotine might exert its
beneficial effects in colitis, we localized a7nAChR in the
guinea-pig colon [32] and more recently, in the murine
colon (Figure 2) utilizing a polyclonal antibody to
a7nAChR (1:50; Abcam). The specificity of the antibody
was confirmed by Western blots and demonstrating
a7nAChR immunoreactivity in the adrenal medulla.
Immunohistochemistry localized a7nAChR protein to
cells in the mucosa and enteric neurons. All a7nAChR-
positive neurons in the myenteric plexus contained nitric
oxide synthase (NOS) a marker of inhibitory motorneur-
ons in the mouse colon. Numerous a7nAChR-ir nerve
fibers were present in the circular muscle layer. Animal
studies have shown that nicotine produces smooth mus-
cle relaxation largely through the release of NO. This
action of nicotine has been confirmed in the human sig-
moid colon and could account for rapid and dramatic
relief of fecal urgency and frequency reported by some
ulcerative colitis patients given nicotine [11].
Little is known about the significance of enteric
nAChRs in inflammation or the function of a7nAChR
in particular. To confirm a7nAChR expression in the
ENS and determine whether inflammation can affect
a7nAChR expression in the gut we isolated the longitu-
dinal muscle with adherent myenteric plexus (LMMP)
from the inflamed colon of DSS-treated (n = 5) and
control (n = 5) mice and a7nAChR expression was ana-
lyzed using real-time reverse transcriptase polymerase
chain reaction (RT-PCR). The level of a7nAChR mRNA
expression in the LMMP was significantly (p <0 . 0 5 )
increased in colitis (See Figure 3) demonstrating that
inflammation can modulate a7nAChR expression and
signaling in the ENS. A well-documented and significant
up-regulation of IL6 mRNA expression was also
observed while the expression of PPAR-g1 and PPAR-g2
remained unchanged (Figure 3). These findings confirm
a7nAChR expression in the ENS and a putative role in
gut inflammation.
Other nAChRs in colitis
Although a great deal of attention has been given to
a7nAChR in peripheral disease and inflammation, it is
premature to assume that this receptor is alone in its
participation in modulating the peripheral inflammatory
status. In fact, nAChR subunit mRNA for a3, a5, b2,
and b4 has been detected in multiple cell types of the
intestine suggesting that, as in the brain, nicotine may
impact upon different inflammatory processes with con-
siderable specificity depending upon the nAChR sub-
types present. Xu et al. [96] reported that mice lacking
a3nAChR or both nAChRb2 and nAChRb4 have similar
autonomic dysfunction of the bowel. Studies by [91]
demonstrated that the a5nAChR might participate in
colitis and the differential response to nicotine. Mice
deficient in a5 n A C h Ra r em o r es u s c e p t i b l et oe x p e r i -
mentally induced colitis than their wild-type controls.
However, transdermal nicotine attenuated the disease
process in both wild type and knockout mice, although
to a greater extent in the knockout mice, suggesting
that the absence of a5nAChR increases the susceptibility
to disease initiation and the presence of a5nAChR in
the wild-type animal appears to enhance the therapeutic
sensitivity to nicotine.
Figure 2 Immunohistochemical localization of a7nAChR in the
murine enteric nervous system. A. Confocal image of a cryostat
section of the colon stained using a polyclonal antibody raised
against the alpha bungarotoxin-sensitive receptor subunit a7nAChR
(1:50; Abcam). The specificity of the antibody was confirmed by
Western blot and demonstrating a7nAChR immunoreactivity in the
adrenal medulla. B. The same section stained using an antibody to
neuronal nitric oxide synthase (nNOS; Upstate Biotechnology). All
a7nAChR-positive neurons express nNOS (arrow), a marker of
inhibitory motorneurons in the murine colon; however, a subset of
nNOS-positive neurons does not express a7nAChR (B; arrowhead).
a7nAChR immunoreactivity is also displayed by immune cells in the
mucosa (arrowhead). Unpublished research.
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Much work remains in terms of understanding the anti-
inflammatory effects of nicotine in obesity-related
inflammation and ulcerative colitis. However, it is now
known that the a7nAChR plays a major role in the anti-
inflammatory effects of nicotine and nicotine attenuates
inflammation in both obesity and ulcerative colitis.
What these findings suggest is the potential use of selec-
tive a7nAChR agonists as a new class of anti-inflamma-
tory drugs. Despite tremendous efforts, obesity and
obesity-related disorders remain at epidemic proportions
and the etiology of ulcerative colitis remains unclear.
Since the inflammatory response is an integral process
in both obesity and ulcerative colitis, controlling the
inflammatory response could ameliorate tissue damage.
The effectiveness of a7nAChR agonists as a drug target
will ultimately depend upon a clear understanding of
the collective biological consequences of peripheral
nAChR expression on inflammation. In addition, it
should also be considered that the development of nico-
tine as a therapeutic intervention has its limitations due
to toxicity related side effects and pharmacological non-
specificity.
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